NYSEHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading TDOC? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround scenario, as Teladoc is currently loss-making but has set ambitious revenue and loss reduction targets. The current thesis state is cautious, given the mixed recent performance and elevated risk factors.
The market seems to have priced in a low level of fragility, indicating that expectations are somewhat justified but may not fully account for the potential volatility in earnings. Teladoc is viewed as cheap compared to its peers, with a notable expectations gap.
Management aims to achieve specific revenue and loss targets for 2026, with some indicators showing they are on track for quarterly goals. However, the overall trajectory remains uncertain, especially given the company's recent history of earnings misses.
The long-term thesis hinges on the company's ability to meet its revenue guidance and manage losses effectively. Additionally, the performance of sector bellwethers like VEEV, BTSG, and TEM will be crucial in determining the broader healthcare momentum that could impact Teladoc.
Over the next 1 to 3 years, Teladoc's success will depend on its execution of financial targets and external sector influences. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This report will give important updates on revenue and losses. It will affect how investors feel.
Confirms one read:Earnings report shows revenue growth and reduced losses.
Confirms the other:Earnings report shows lower revenue or bigger losses.
Why it matters: Meeting this guidance shows Teladoc can maintain revenue levels. It is key for growth.
Confirms:Q2 2026 revenue reported within the range of $597 - $626 million.
Disproves:Q2 2026 revenue falls below $597 million.
Why it matters: A stable or improving growth rate is crucial for meeting full-year revenue guidance. It indicates demand for services.
Confirms:The quarterly revenue growth rate stays the same or gets better than before.
Disproves:The quarterly revenue growth rate drops a lot compared to earlier quarters.
Why it matters: If healthcare sector growth speeds up, it could benefit Teladoc. This would signal a stronger market environment.
Confirms:Healthcare sector revenue growth exceeds 12% year over year.
Disproves:Healthcare sector revenue growth stays below 10% year over year.
Why it matters: Hitting this revenue goal for the year is key for Teladoc's growth.
Confirms:Full-year revenue reported at or above $2,481 million.
Disproves:Full-year revenue was less than $2,481 million.
Why it matters: A smaller net loss shows better cost control. This means more chances to make money.
Confirms:Net loss per share reported between $0.75 and $1.05.
Disproves:Net loss per share remains worse than $1.05.
Why it matters: BetterHelp's drop in revenue hurts overall performance. Stabilizing is key for future growth.
Confirms:BetterHelp's revenue grew by -6.5% or better compared to last year.
Disproves:BetterHelp's revenue growth gets worse if it goes below -6.5% year-over-year.
